Rebecca Redman

Rebecca Redman

Auto-generated profile, based on publicly available information

Rebecca Redman

Division of Medical Oncology & Hematology, Brown Cancer Center, University of Louisville, Louisville, KY, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RFRobert L Ferris
Robert L Ferris
RLRom Leidner
Rom Leidner
CCChristine Chung
Christine Chung
AJAntonio Jimeno
Antonio Jimeno
SLSylvia M Lee
Sylvia M Lee
ECEzra E W Cohen
Ezra E W Cohen
Background: Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a high recurrence rate after first-line immunotherapy or chemoimmunotherapy. The presence of a high density of tumor-infiltrating lymphocytes (TILs) in HNSCC tumors was shown to be associated with improved clinical outcomes. One-time autologous TIL cell therapy was evaluated in patients with recurrent and/or metastatic HNSCC. Methods: C-145-03 (NCT03083873) was a phase 2 study of TIL in patients with recurrent and/or metastatic HNSCC assigned to 1 of 4 treatment cohorts: cohort 1, non-cryopreserved TIL; cohort 2, cryopreserved lifileucel (22-day manufacturing); cohort 3, cryopreserved lifileucel (16-day manufacturing); cohort 4, cryopreserved LN-145-S1 programmed cell death protein-1 (PD-1) selected. Patients underwent tumor resection for TIL generation. After preparative non-myeloablative lymphodepletion, patients received a single infusion of TIL followed by interleukin-2 (IL-2) infusion(s). The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria for Solid Tumors (RECIST) V.1.1. Secondary endpoints were investigator-assessed duration of response (DOR), disease control rate (DCR), progression-free survival, overall survival, and incidence of treatment-emergent adverse events. Results: Overall, 53 patients received TIL: cohort 1 (n=8), cohort 2 (n=17), cohort 3 (n=16), cohort 4 (n=12). Median age was 57 years and most patients were males (87%; 46/53) with stage IV disease (98%; 52/53). Patients had a median of two prior lines of systemic therapy; 87% (46/53) of patients had prior anti-PD-1/programmed cell death ligand-1 therapy and 72% (38/53) had prior chemotherapy. The ORR was 11% (6/53) with six patients achieving partial response (cohort 1, n=3; cohort 2, n=1; cohort 4, n=2). At median follow-up of 17.9 months, the median DOR was 7.6 months. The DCR was 76% (40/53); 64% (34/53) of patients had stable disease. The safety profile was consistent with known toxicities associated with non-myeloablative lymphodepletion and IL-2 administration. Conclusions: This study demonstrated the feasibility of consistently generating sufficient TIL from HNSCC tumors. Results from this study suggest TIL cell therapy may serve as a potential treatment option for patients with HNSCC and support further development, including TIL cell therapy combined with immune checkpoint inhibitors or other agents or with other TIL products. Trial registration number: NCT03083873.

1 November 2015 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
CCChristopher R. Cannavino
Christopher R. Cannavino
BCBibiana Castaneda-Ruiz
Bibiana Castaneda-Ruiz
RRRebecca Redman
Rebecca Redman
OGOscar Go
Oscar Go
ICIolanda Cirillo
Iolanda Cirillo
JBJohn S. Bradley
John S. Bradley
Three multicenter, randomized, controlled studies evaluated doripenem in children 3 months to <18 years of age, with complicated intra-abdominal or urinary tract infections and bacterial pneumonia.In the 66 patients treated with doripenem before early termination of the studies for nonsafety reasons, doripenem was safe and generally well tolerated. Low enrollment limited ability to assess benefits and risks of doripenem in children.

21 May 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PGPetros Grivas
Petros Grivas
EGElena Garralda
Elena Garralda
FMFunda Meric-Bernstam
Funda Meric-Bernstam
IMIngo K. Mellinghoff
Ingo K. Mellinghoff
LGLipika Goyal
Lipika Goyal
KFKeith T. Flaherty
Keith T. Flaherty
Purpose: This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1–3, in patients with solid tumors harboring a functional FGFR1–3 fusion. Patients and Methods: Eligible adults had a previously treated locally advanced (unresectable) or metastatic biliary tract (cohort 1), urothelial (cohort 2), or another histologic cancer type (cohort 3). Debio 1347 was administered at 80 mg once daily, continuously, in 28-day cycles. The primary endpoint was the objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, pharmacokinetics, and incidence of adverse events. Results: Between March 22, 2019, and January 8, 2020, 63 patients were enrolled and treated, 30 in cohort 1, 4 in cohort 2, and 29 in cohort 3. An unplanned preliminary statistical review showed that the efficacy of Debio 1347 was lower than predicted, and the trial was terminated. In total, 3 of 58 evaluable patients had partial responses, representing an objective response rate of 5%, with a further 26 (45%) having stable disease (≥6 weeks duration). Grade ≥3 treatment-related adverse events occurred in 22 (35%) of 63 patients, with the most common being hyperphosphatemia (13%) and stomatitis (5%). Two patients (3%) discontinued treatment due to adverse events. Conclusions: Debio 1347 had manageable toxicity; however, the efficacy in patients with tumors harboring FGFR fusions did not support further clinical evaluation in this setting. Our transcriptomic-based analysis characterized in detail the incidence and nature of FGFR fusions across solid tumors. See related commentary by Hage Chehade et al., p. 4549

1 January 2019 in Oral Oncology
Verified
Journal Article
Closed access
MMMichael E. May
Michael E. May
ECElizabeth D. Cash
Elizabeth D. Cash
CSCraig L. Silverman
Craig L. Silverman
RRRebecca A. Redman
Rebecca A. Redman
CPCesar A. Perez
Cesar A. Perez
NDNeal Dunlap
Neal Dunlap

1 August 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ICIolanda Cirillo
Iolanda Cirillo
NVNicole Vaccaro
Nicole Vaccaro
BCBibiana Castaneda-Ruiz
Bibiana Castaneda-Ruiz
RRRebecca Redman
Rebecca Redman
VCVeerle Cossey
Veerle Cossey
Karel AllegaertKarel Allegaert
Karel Allegaert
Doripenem, a parenteral carbapenem with broad-spectrum activity against aerobic Gram-negative and Gram-positive and anaerobic pathogens, is currently approved for use in adults in the United States and European Union. Single-dose doripenem pharmacokinetics in 52 infants <12 weeks in chronological age were investigated in this phase 1 study. Hospitalized, medically stable infants <12 weeks in chronological age were stratified into 6 groups based on chronological and gestational age designed to reflect increasing renal maturation and decreasing volume of distribution ( V z ) for β-lactam antimicrobials during the first 3 months of life. Subjects received single-dose doripenem (5 mg/kg of body weight for <8 weeks and 8 mg/kg for ≥8 weeks in chronological age) administered intravenously over 1 h. Plasma samples were obtained immediately before the end of the infusion and 1.5, 3, and 7 h after the start of the infusion. Urine was obtained by indwelling catheter during the 8 h following infusion. Doripenem showed linear pharmacokinetics across the 6 age groups. Neonates (4 weeks. Mean V z was highest in subjects with the earliest gestational age (<32 weeks): 0.564 liter/kg for neonates and 0.548 liter/kg for infants. Single-dose pharmacokinetics of doripenem administered as a 1-hour infusion in term and preterm infants <12 weeks in chronological age were similar to what has been observed in neonates and very young infants with other carbapenems. Single-dose doripenem was generally safe and well tolerated. (This study has been registered with ClinicalTrials.gov under registration no. NCT01381848 and with EudraCT under registration no. 2009-014387-20.)

1 December 2020 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
SKSujita Khanal
Sujita Khanal
JSJohn D. Strickley
John D. Strickley
THThinh Ha
Thinh Ha
SDShadmehr Demehri
Shadmehr Demehri
SGShin-Je Ghim
Shin-Je Ghim
JJJoongho John Joh
Joongho John Joh